The White House has no immediate plans to require insurance companies to cover in vitro fertilization (IVF), despite U.S. President Donald Trump’s campaign pledge to expand access to fertility treatments, according to The Washington Post.
Earlier this year, President Trump signed an executive order aimed at expanding IVF access and reducing treatment costs for Americans seeking fertility care. The order directed federal agencies to find ways to make the popular treatment more affordable and accessible. However, White House officials say legal constraints prevent them from mandating insurance coverage without Congressional approval.
While the administration maintains that increasing IVF access is still a policy priority, no legislation has been introduced in Congress to address the insurance coverage gap. Without such a bill, the federal government cannot compel private insurers to include IVF in their health plans.
IVF has become an increasingly sought-after solution for couples and individuals facing infertility, but the high cost—often exceeding $15,000 per cycle in the U.S.—remains a major barrier. Advocates argue that insurance mandates could help millions access treatment, while opponents cite concerns over cost implications for the healthcare system.
The issue has drawn renewed national attention following several state-level legislative battles over fertility treatment access. In some states, lawmakers have moved to protect or expand IVF coverage, while others have faced legal and political challenges that could limit availability.
Reuters was unable to independently verify the Washington Post report, and the White House did not respond to a request for comment. For now, the future of federally mandated IVF insurance coverage remains uncertain, leaving millions of hopeful parents in limbo as the debate over fertility rights and healthcare policy continues.


Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Trump Threatens 50% Tariff on Canadian Aircraft Amid Escalating U.S.-Canada Trade Dispute
Trump Extends AGOA Trade Program for Africa Through 2026, Supporting Jobs and U.S.-Africa Trade
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Norway Opens Corruption Probe Into Former PM and Nobel Committee Chair Thorbjoern Jagland Over Epstein Links
U.S. Eases Venezuela Oil Sanctions to Boost American Investment After Maduro Ouster
ICE Blocked From Entering Ecuador Consulate in Minneapolis During Immigration Operation
South Korea Assures U.S. on Trade Deal Commitments Amid Tariff Concerns
Ukraine-Russia Talks Yield Major POW Swap as U.S. Pushes for Path to Peace
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change
Marco Rubio Steps Down as Acting U.S. Archivist Amid Federal Law Limits
New York Legalizes Medical Aid in Dying for Terminally Ill Patients
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Faith Leaders Arrested on Capitol Hill During Protest Against Trump Immigration Policies and ICE Funding 



